- Conditions
- Advanced Solid Tumor, Non-small Cell Lung Cancer, Colorectal Cancer, Squamous Cell Carcinoma, Ovarian Carcinoma, Peritoneal Carcinoma, Fallopian Tube Cancer, Head and Neck Squamous Cell Carcinoma, Triple Negative Breast Cancer
- Interventions
- NM21-1480
- Biological
- Lead sponsor
- Numab Therapeutics AG
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 14
- States / cities
- Fort Collins, Colorado • Augusta, Georgia • New Orleans, Louisiana + 11 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 3,355
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Advanced or Metastatic Solid Tumors
- Interventions
- BH3120, pembrolizumab
- Drug
- Lead sponsor
- Hanmi Pharmaceutical Company Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 245 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 5
- States / cities
- Tampa, Florida • Grand Rapids, Michigan • Cincinnati, Ohio + 2 more
- Conditions
- Advanced Solid Tumors
- Interventions
- ASKG915, Paclitaxel + Bevacizumab, Fruquintinib, Docetaxel
- Biological · Drug
- Lead sponsor
- AskGene Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 594 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 2
- States / cities
- New York, New York • Pittsburgh, Pennsylvania
- Conditions
- Non-Small-Cell Lung Carcinoma, Prostate Cancer, Bladder Cancer, Urothelial Carcinoma
- Interventions
- vorinostat (suberoylanilide hydroxamic acid), docetaxel
- Drug
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Advanced Solid Tumors
- Interventions
- Calderasib, Pembrolizumab, carboplatin, pemetrexed, cetuximab, oxaliplatin, leucovorin, 5-fluorouracil
- Drug · Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 830 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2030
- U.S. locations
- 6
- States / cities
- Tampa, Florida • Grand Rapids, Michigan • Hackensack, New Jersey + 3 more
- Conditions
- Solid Tumors
- Interventions
- AV-203
- Biological
- Lead sponsor
- AVEO Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Atlanta, Georgia • San Antonio, Texas
- Conditions
- Vulvar Adenocarcinoma, PDAC - Pancreatic Ductal Adenocarcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma, Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Small Cell Carcinoma of Lung, Colorectal Cancer, Hormone Receptor Positive Breast Carcinoma
- Interventions
- AVA6103
- Drug
- Lead sponsor
- Avacta Life Sciences Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 174 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 3
- States / cities
- Grand Rapids, Michigan • Irving, Texas • Fairfax, Virginia
- Conditions
- Solid Tumors
- Interventions
- nesvacumab (REGN910/ SAR307746), aflibercept (ziv-aflibercept)
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 5
- States / cities
- Indianapolis, Indiana • New York, New York • Oklahoma City, Oklahoma + 2 more
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- PEG-interferon alfa-2b, temozolomide
- Biological · Drug
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 18 Years to 120 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2002
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire
- Conditions
- Locally Advanced/Metastatic Solid Tumors
- Interventions
- HY-0102
- Drug
- Lead sponsor
- Shanghai HyaMab Biotech Co.,Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 3
- States / cities
- Orlando, Florida • Las Vegas, Nevada • Tyler, Texas
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- NKTR-214
- Drug
- Lead sponsor
- Nektar Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 3
- States / cities
- New Haven, Connecticut • Portland, Oregon • Houston, Texas
- Conditions
- Solid Tumor Malignancies
- Interventions
- KQB548
- Drug
- Lead sponsor
- Kumquat Biosciences Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 13
- States / cities
- La Jolla, California • Los Angeles, California • Denver, Colorado + 10 more
- Conditions
- Hematologic Malignancy, Solid Tumor, Advanced Malignancies
- Interventions
- Pelabresib
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Jacksonville, Florida • Chicago, Illinois + 2 more
- Conditions
- Advanced Solid Tumors
- Interventions
- indibulin, capecitabine
- Drug
- Lead sponsor
- Alaunos Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 3
- States / cities
- Indianapolis, Indiana • Las Vegas, Nevada • Vancouver, Washington
- Conditions
- Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- everolimus, lapatinib ditosylate
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2013
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Sacramento, California • Aurora, Colorado + 3 more
- Conditions
- Lymphoma, Advanced Solid Tumors
- Interventions
- E7766
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 6
- States / cities
- New Haven, Connecticut • Miami, Florida • Boston, Massachusetts + 1 more
- Conditions
- Neoplasms
- Interventions
- [177Lu]-NeoB, [68Ga]-NeoB, LCZ696
- Drug
- Lead sponsor
- Advanced Accelerator Applications
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 6
- States / cities
- Duarte, California • Stanford, California • Baltimore, Maryland + 3 more
- Conditions
- Melanoma (Skin Cancer), HER2-low Hormone Receptor Positive Breast Cancer
- Interventions
- AMXT 1501 Dicaprate, DFMO, Fulvestrant, Capivasertib, Pembrolizumab
- Drug
- Lead sponsor
- Aminex Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 20
- States / cities
- Tucson, Arizona • La Jolla, California • Los Angeles, California + 15 more
- Conditions
- PD-L1-selected Solid Tumors
- Interventions
- Tiragolumab and Atezolizumab IV FDC
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Spokane, Washington
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- carbendazim
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2000
- U.S. locations
- 2
- States / cities
- Fort Sam Houston, Texas • San Antonio, Texas
- Conditions
- Neoplasms
- Interventions
- carboplatin + SU011248 (sunitinib) + paclitaxel
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 4
- States / cities
- Detroit, Michigan • Philadelphia, Pennsylvania • Houston, Texas + 1 more
- Conditions
- Metastatic Solid Tumor, Advanced Solid Tumor
- Interventions
- CHS-114, Toripalimab, 5 Fluorouracil, Cisplatin
- Drug
- Lead sponsor
- Coherus Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 154 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 20
- States / cities
- Tucson, Arizona • Duarte, California • Aurora, Colorado + 16 more
- Conditions
- Solid Tumor, Adult
- Interventions
- Highly selective FGFR1-3 inhibitor
- Drug
- Lead sponsor
- 3D Medicines (Beijing) Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- Santa Monica, California
- Conditions
- Advanced Solid Tumors
- Interventions
- obrindatamab, retifanlimab
- Biological
- Lead sponsor
- MacroGenics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 10
- States / cities
- Duarte, California • Los Angeles, California • Newport Beach, California + 6 more